American Oncology Institute, Mangalagiri pioneers innovative approach in breast cancer surgery 

Paravertebral block (PVB) along with the pectoral nerves (PECS) block as the primary anaesthetic technique was utilised

American Oncology Institute (AOI) in Mangalagiri announced a groundbreaking advancement in the treatment of breast cancer. Recently, AOI successfully treated three high-risk patients with carcinoma breast using a novel anaesthetic technique, marking a significant milestone in cancer care.

AOI in Mangalagiri, Vijayawada introduced a pioneering approach by utilising Paravertebral block (PVB) along with the pectoral nerves (PECS) block as the primary anaesthetic technique. This innovative method allowed the patients to undergo MRM surgery safely and successfully, without the risks associated with general anaesthesia.

Dr Kalyan Polavarapu, Surigical Oncologist, AOI, commented, “Treating patients with breast cancer who also suffer from significant comorbidities presents a unique set of challenges. Our goal is to provide the best possible care while minimising risks and ensuring patient safety.”

Dr Sreedevi, Consultant anesthesiologist, AOI, commented, Paravertebral block (with ultrasound guidance )  involves administering a local anaesthetic near the spinal nerves, resulting in somatic and sympathetic nerve blockade. This technique boasts a low incidence of adverse effects, making it a safe and effective alternative for high-risk patients. By implementing Paravertebral and PECS blocks, we were able to tailor the anaesthetic approach to each patient’s individual needs, resulting in successful surgical outcomes.”

Mahendra Reddy, Regional Chief Operating Officer (RCOO), AOI, Vijayawada, expressed his pride in the hospital’s achievement, stating, “At AOI, we are committed to pushing the boundaries of cancer care and delivering innovative solutions to improve patient outcomes. The successful treatment of these high-risk breast cancer patients underscores our dedication to excellence and reinforces our position as a leader in oncology care.”